FineImmu

FineImmu, established in 2018, is a biopharmaceutical and biotechnology startup dedicated to revolutionizing healthcare with advanced cell therapy drugs and precision immunodiagnostic products. The company's slogan "Creating future health with advanced cell therapy drugs and precision immunodiagnostic products" encapsulates its mission. FineImmu's innovative drug specializes in forecasting the anti-tumor immune response of PD-1 and PD-L1, as well as the efficacy of immune checkpoint inhibitors like CTLA4. In August 3, 2022, the company secured a significant CNY90.00M in the Seed Round investment from prominent investors including Panacea Venture, Beijing Huafang Investment, Revel Ventures, and Yabao Investment. FineImmu's presence in Health Care, Biopharma, and Biotechnology industries positions it at the forefront of the rapidly evolving biotech landscape. For further details, the company can be contacted through phone or physical address.